Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis

B. Truong, N. Rich-Garg, Benjamin (Ben) Ehst, Atulya (Atul) Deodhar, J. H. Ku, K. Vakil-Gilani, A. Danve, A. Blauvelt

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Innovation: What is already known about the topic: psoriasis (PsO) is a common skin disease with major impact on quality of life (QoL). Patient-reported data on QoL from large number of PsO patients with and without psoriatic arthritis (PsA) are limited. What this study adds: In a large cohort referred to a university psoriasis center, patients with PsO and concomitant PsA (~30% in this group) had greater degrees of skin and nail involvement and experienced greater negative impacts on QoL. Despite large numbers of patients with moderate-to-severe disease, use of systemic therapy by community practitioners was uncommon. Background: PsO and PsA are common diseases that have marked adverse impacts on QoL. The disease features and patient-reported QoL data comparing PsO and PsA patients are limited. Objective: To identify and compare demographics, clinical disease characteristics, and QoL scores in a large cohort of PsO patients with and without PsA. Methods: All PsO patients seen in a psoriasis specialty clinic, named the Center of Excellence for Psoriasis and Psoriatic Arthritis, were enrolled in an observational cohort. Demographic, QoL, and clinical data were collected from patient-reported questionnaires and from physical examinations performed by Center of Excellence for Psoriasis and Psoriatic Arthritis dermatologists and a rheumatologists. Cross sectional descriptive data were collected and comparisons between patients with PsO alone and those with concomitant PsA are presented. Results: A total of 568 patients were enrolled in the database. Mean age of PsO onset was 28 years and mean disease duration was 18 years. Those with family history had an earlier onset of PsO by ~7 years. Mean body surface area involvement with PsO was 14%. Mean body mass index was 30.7. Prevalence of PsA was 29.8%. PsA patients had a higher mean body surface area compared to patients with PsO alone (16.7% vs 13.4%, P

Original languageEnglish (US)
Pages (from-to)563-569
Number of pages7
JournalClinical, Cosmetic and Investigational Dermatology
Volume8
DOIs
StatePublished - Nov 4 2015

Fingerprint

Psoriatic Arthritis
Psoriasis
Quality of Life
Demography
Body Surface Area
Nails
Age of Onset

Keywords

  • Epidemiology
  • Patient-reported outcomes
  • Psoriasis
  • Psoriatic arthritis
  • Quality of life
  • Treatments

ASJC Scopus subject areas

  • Dermatology

Cite this

Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. / Truong, B.; Rich-Garg, N.; Ehst, Benjamin (Ben); Deodhar, Atulya (Atul); Ku, J. H.; Vakil-Gilani, K.; Danve, A.; Blauvelt, A.

In: Clinical, Cosmetic and Investigational Dermatology, Vol. 8, 04.11.2015, p. 563-569.

Research output: Contribution to journalArticle

@article{2ea870334f9348daa87337a926495911,
title = "Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis",
abstract = "Innovation: What is already known about the topic: psoriasis (PsO) is a common skin disease with major impact on quality of life (QoL). Patient-reported data on QoL from large number of PsO patients with and without psoriatic arthritis (PsA) are limited. What this study adds: In a large cohort referred to a university psoriasis center, patients with PsO and concomitant PsA (~30{\%} in this group) had greater degrees of skin and nail involvement and experienced greater negative impacts on QoL. Despite large numbers of patients with moderate-to-severe disease, use of systemic therapy by community practitioners was uncommon. Background: PsO and PsA are common diseases that have marked adverse impacts on QoL. The disease features and patient-reported QoL data comparing PsO and PsA patients are limited. Objective: To identify and compare demographics, clinical disease characteristics, and QoL scores in a large cohort of PsO patients with and without PsA. Methods: All PsO patients seen in a psoriasis specialty clinic, named the Center of Excellence for Psoriasis and Psoriatic Arthritis, were enrolled in an observational cohort. Demographic, QoL, and clinical data were collected from patient-reported questionnaires and from physical examinations performed by Center of Excellence for Psoriasis and Psoriatic Arthritis dermatologists and a rheumatologists. Cross sectional descriptive data were collected and comparisons between patients with PsO alone and those with concomitant PsA are presented. Results: A total of 568 patients were enrolled in the database. Mean age of PsO onset was 28 years and mean disease duration was 18 years. Those with family history had an earlier onset of PsO by ~7 years. Mean body surface area involvement with PsO was 14{\%}. Mean body mass index was 30.7. Prevalence of PsA was 29.8{\%}. PsA patients had a higher mean body surface area compared to patients with PsO alone (16.7{\%} vs 13.4{\%}, P",
keywords = "Epidemiology, Patient-reported outcomes, Psoriasis, Psoriatic arthritis, Quality of life, Treatments",
author = "B. Truong and N. Rich-Garg and Ehst, {Benjamin (Ben)} and Deodhar, {Atulya (Atul)} and Ku, {J. H.} and K. Vakil-Gilani and A. Danve and A. Blauvelt",
year = "2015",
month = "11",
day = "4",
doi = "10.2147/CCID.S90270",
language = "English (US)",
volume = "8",
pages = "563--569",
journal = "Clinical, Cosmetic and Investigational Dermatology",
issn = "1178-7015",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis

AU - Truong, B.

AU - Rich-Garg, N.

AU - Ehst, Benjamin (Ben)

AU - Deodhar, Atulya (Atul)

AU - Ku, J. H.

AU - Vakil-Gilani, K.

AU - Danve, A.

AU - Blauvelt, A.

PY - 2015/11/4

Y1 - 2015/11/4

N2 - Innovation: What is already known about the topic: psoriasis (PsO) is a common skin disease with major impact on quality of life (QoL). Patient-reported data on QoL from large number of PsO patients with and without psoriatic arthritis (PsA) are limited. What this study adds: In a large cohort referred to a university psoriasis center, patients with PsO and concomitant PsA (~30% in this group) had greater degrees of skin and nail involvement and experienced greater negative impacts on QoL. Despite large numbers of patients with moderate-to-severe disease, use of systemic therapy by community practitioners was uncommon. Background: PsO and PsA are common diseases that have marked adverse impacts on QoL. The disease features and patient-reported QoL data comparing PsO and PsA patients are limited. Objective: To identify and compare demographics, clinical disease characteristics, and QoL scores in a large cohort of PsO patients with and without PsA. Methods: All PsO patients seen in a psoriasis specialty clinic, named the Center of Excellence for Psoriasis and Psoriatic Arthritis, were enrolled in an observational cohort. Demographic, QoL, and clinical data were collected from patient-reported questionnaires and from physical examinations performed by Center of Excellence for Psoriasis and Psoriatic Arthritis dermatologists and a rheumatologists. Cross sectional descriptive data were collected and comparisons between patients with PsO alone and those with concomitant PsA are presented. Results: A total of 568 patients were enrolled in the database. Mean age of PsO onset was 28 years and mean disease duration was 18 years. Those with family history had an earlier onset of PsO by ~7 years. Mean body surface area involvement with PsO was 14%. Mean body mass index was 30.7. Prevalence of PsA was 29.8%. PsA patients had a higher mean body surface area compared to patients with PsO alone (16.7% vs 13.4%, P

AB - Innovation: What is already known about the topic: psoriasis (PsO) is a common skin disease with major impact on quality of life (QoL). Patient-reported data on QoL from large number of PsO patients with and without psoriatic arthritis (PsA) are limited. What this study adds: In a large cohort referred to a university psoriasis center, patients with PsO and concomitant PsA (~30% in this group) had greater degrees of skin and nail involvement and experienced greater negative impacts on QoL. Despite large numbers of patients with moderate-to-severe disease, use of systemic therapy by community practitioners was uncommon. Background: PsO and PsA are common diseases that have marked adverse impacts on QoL. The disease features and patient-reported QoL data comparing PsO and PsA patients are limited. Objective: To identify and compare demographics, clinical disease characteristics, and QoL scores in a large cohort of PsO patients with and without PsA. Methods: All PsO patients seen in a psoriasis specialty clinic, named the Center of Excellence for Psoriasis and Psoriatic Arthritis, were enrolled in an observational cohort. Demographic, QoL, and clinical data were collected from patient-reported questionnaires and from physical examinations performed by Center of Excellence for Psoriasis and Psoriatic Arthritis dermatologists and a rheumatologists. Cross sectional descriptive data were collected and comparisons between patients with PsO alone and those with concomitant PsA are presented. Results: A total of 568 patients were enrolled in the database. Mean age of PsO onset was 28 years and mean disease duration was 18 years. Those with family history had an earlier onset of PsO by ~7 years. Mean body surface area involvement with PsO was 14%. Mean body mass index was 30.7. Prevalence of PsA was 29.8%. PsA patients had a higher mean body surface area compared to patients with PsO alone (16.7% vs 13.4%, P

KW - Epidemiology

KW - Patient-reported outcomes

KW - Psoriasis

KW - Psoriatic arthritis

KW - Quality of life

KW - Treatments

UR - http://www.scopus.com/inward/record.url?scp=84946917209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946917209&partnerID=8YFLogxK

U2 - 10.2147/CCID.S90270

DO - 10.2147/CCID.S90270

M3 - Article

AN - SCOPUS:84946917209

VL - 8

SP - 563

EP - 569

JO - Clinical, Cosmetic and Investigational Dermatology

JF - Clinical, Cosmetic and Investigational Dermatology

SN - 1178-7015

ER -